Charles J Rosser

List of Publications by Year
in descending order

72 papers	2,533 citations	172457 29 h-index	206112 48 g-index
73 all docs	73 docs citations	73 times ranked	3216 citing authors

#	Article	IF	Citations
1	Dichloroacetate (DCA) sensitizes both wildâ€type and over expressing Bclâ€2 prostate cancer cells in vitro to radiation. Prostate, 2008, 68, 1223-1231.	2.3	168
2	Persistent Exposure to Mycoplasma Induces Malignant Transformation of Human Prostate Cells. PLoS ONE, 2009, 4, e6872.	2.5	134
3	Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic Profiling. Journal of Proteome Research, 2007, 6, 2631-2639.	3.7	128
4	Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification. Clinical Cancer Research, 2011, 17, 3349-3359.	7.0	123
5	A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2012, 7, e47469.	2.5	84
6	Prostate Specific Antigen Bounce Phenomenon After External Beam Radiation for Clinically Localized Prostate Cancer.. Journal of Urology, 2002, 168, 2001-2005.	0.4	80
7	Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion. PLoS ONE, 2014, 9, e96705.	2.5	79
8	CCL18 in a Multiplex Urine-Based Assay for the Detection of Bladder Cancer. PLoS ONE, 2012, 7, e37797.	2.5	76
9	A Candidate Molecular Biomarker Panel for the Detection of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2149-2158.	2.5	73
10	Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer, 2014, 14, 310.	2.6	72
11	An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nature Communications, 2021, 12, 4906.	12.8	67
12	Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Therapy, 2002, 9, 687-691.	4.6	66
13	Bladder Cancerâ€“Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 444-453.	2.5	65
14	Targeting Plasminogen Activator Inhibitor-1 Inhibits Angiogenesis and Tumor Growth in a Human Cancer Xenograft Model. Molecular Cancer Therapeutics, 2013, 12, 2697-2708.	4.1	63
15	p37 induces tumor invasiveness. Molecular Cancer Therapeutics, 2005, 4, 1031-1038.	4.1	59
16	Urinary BTA: indicator of bladder cancer or of hematuria. World Journal of Urology, 2012, 30, 869-873.	2.2	59
17	IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urology, 2012, 12, 12.	1.4	59
18	Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1340-1345.	2.5	57

#	Article	IF	Citations
19	Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Molecular Cancer Therapeutics, 2007, 6, 101-111.	4.1	56
20	Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urology, 2012, 79, 1185.e1-1185.e6.	1.0	47
21	Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urology, 2012, 12, 23.	1.4	46
22	Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. Cells, 2019, 8, 212.	4.1	46
23	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1804-1812.	2.5	44
24	Multiplex Protein Signature for the Detection of Bladder Cancer in Voided Urine Samples. Journal of Urology, 2013, 190, 2257-2262.	0.4	42
25	PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation. Molecular Cancer Research, 2014, 12, 322-334.	3.4	42
26	Diagnostic Potential of Urinary Î±1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. Journal of Urology, 2012, 188, 2377-2383.	0.4	35
27	A multiplex immunoassay for the non-invasive detection of bladder cancer. Journal of Translational Medicine, 2016, 14, 31.	4.4	34
28	Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urology, 2009, 9, 12.	1.4	33
29	Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Therapy, 2002, 9, 681-686.	4.6	31
30	Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagnostic Pathology, 2014, 9, 200.	2.0	30
31	A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget, 2016, 7, 7253-7267.	1.8	30
32	Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urology, 2013, 13, 42.	1.4	26
33	Simultaneous multi-analyte urinary protein assay for bladder cancer detection. BMC Biotechnology, 2014, 14, 24.	3.3	25
34	Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. Theranostics, 2019, 9, 853-867.	10.0	25
35	A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. Journal of Translational Medicine, 2016, 14, 287.	4.4	24
36	Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-GuÃ©rin (BCG) for the Treatment of Bladder Cancer. OncoImmunology, 2021, 10, 1912885.	4.6	24

#	Article	IF	Citations
37	Diagnostic performance of Oncuriaâ„¢, a urinalysis test for bladder cancer. Journal of Translational Medicine, 2021, 19, 141.	4.4	24
38	The dynamic roles of the bladder tumour microenvironment. Nature Reviews Urology, 2022, 19, 515-533.	3.8	24
39	Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Review of Proteomics, 2009, 6, 507-514.	3.0	23
40	Diagnostic biomarkers in non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 2009-2016.	2.2	22
41	Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. Oncotarget, 2018, 9, 7101-7111.	1.8	21
42	Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer, 2014, 14, 86.	2.6	19
43	Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. Oncotarget, 2017, 8, 99707-99721.	1.8	19
44	Intravesical ALT-803 for BCG-unresponsive Bladder Cancer â€“ A Case Report. Urology Case Reports, 2017, 14, 15-17.	0.3	18
45	On the brink of extinction: the future of translational physician-scientists in the United States. Journal of Translational Medicine, 2017, 15, 88.	4.4	18
46	Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. Journal of Translational Medicine, 2019, 17, 29.	4.4	18
47	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
48	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications, 2022, 13, 1487.	12.8	17
49	Analytical validation of ONCURIAâ„¢ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection. Practical Laboratory Medicine, 2020, 22, e00189.	1.3	15
50	Vitamin D receptor upregulates lncRNA TOPORS-AS1 which inhibits the Wnt/Î²-catenin pathway and associates with favorable prognosis of ovarian cancer. Scientific Reports, 2021, 11, 7484.	3.3	14
51	Dual targeting of Bcl-2 and VEGF: A potential strategy to improve therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 421-429.	1.6	13
52	Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature. Diagnostics, 2019, 9, 166.	2.6	12
53	CXCL1 is elevated in the urine of bladder cancer patients. SpringerPlus, 2015, 4, 610.	1.2	10
54	Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma. Diagnostics, 2020, 10, 14.	2.6	9

#	Article	IF	Citations
55	Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomarkers, 2022, 33, 151-157.	1.7	9
56	A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1361-1366.	2.5	8
57	Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model. Journal of Translational Medicine, 2020, 18, 57.	4.4	8
58	The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer. Journal of Racial and Ethnic Health Disparities, 2015, 2, 124-131.	3.2	6
59	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. Methods in Molecular Biology, 2018, 1655, 251-273.	0.9	6
60	UroSEEK gene panel for bladder cancer surveillance. Translational Andrology and Urology, 2019, 8, S546-S549.	1.4	6
61	Gene therapy for superficial bladder cancer. Expert Review of Anticancer Therapy, 2001, 1, 531-540.	2.4	5
62	Influencing Factors on the Oncuriaâ„¢ Urinalysis Assay: An Experimental Model. Diagnostics, 2021, 11, 1023.	2.6	5
63	Clinical Utility of Oncuriaâ„¢, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancerâ€"A Pilot Study. Diagnostics, 2022, 12, 131.	2.6	4
64	Todayâ€™s discoveries to tomorrowâ€™s care: cancer biomarkers revisited. Biomarkers in Medicine, 2010, 4, 491-493.	1.4	3
65	PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. Scientific Reports, 2022, 12, .	3.3	3
66	Diagnostic Potential of Urinary <alpha>1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. Journal of Urology, 2013, , .	0.4	2
67	Nutritional implications for quality of life in bladder cancer survivors. Translational Andrology and Urology, 2018, 7, S688-S691.	1.4	1
68	Use of Bladder Sparing Surgery for Muscle Invasive Bladder Cancer by Life Expectancy at Diagnosis. Urology Practice, 2021, 8, 94-99.	0.5	1
69	Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection. Bladder Cancer, 2021, 7, 121-131.	0.4	0
70	Localization of plasminogen activator inhibitor type 1 and 2 in preimplantation mouse development in vitro. Ankara Universitesi Veteriner Fakultesi Dergisi, 0, , .	1.0	0
71	Case Study of Noni Extract in Men with Very Low-Risk or Low-Risk Prostate Cancer. Hawai'i Journal of Health & Social Welfare, 2021, 80, 242-250.	0.2	0
72	The Molecular Twin platform: a novel machine learning tool for democratization of precision cancer medicine.. Journal of Clinical Oncology, 2022, 40, e13546-e13546.	1.6	0